SkyePharma granted to Endo, the North Merican rights to two of SkyePharma’s clinical stage compounds and options on early-stage compounds. In a separate technology access deal, SkyePharma and Enzon will jointly develop products based on SkyePharma’s drug delivery technology and Enzon’s PEG modification technology.